ATE455300T1 - Verfahren und zusammensetzungen zum auslösen einer immunantwort - Google Patents

Verfahren und zusammensetzungen zum auslösen einer immunantwort

Info

Publication number
ATE455300T1
ATE455300T1 AT02805706T AT02805706T ATE455300T1 AT E455300 T1 ATE455300 T1 AT E455300T1 AT 02805706 T AT02805706 T AT 02805706T AT 02805706 T AT02805706 T AT 02805706T AT E455300 T1 ATE455300 T1 AT E455300T1
Authority
AT
Austria
Prior art keywords
ckbeta8
compositions
discovered
inventors
methods
Prior art date
Application number
AT02805706T
Other languages
German (de)
English (en)
Inventor
Thomas Schall
Zhenhua Miao
Robert Berahovich
Zheng Wei
Maureen Howard
Brett Premack
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Application granted granted Critical
Publication of ATE455300T1 publication Critical patent/ATE455300T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
AT02805706T 2002-05-07 2002-10-21 Verfahren und zusammensetzungen zum auslösen einer immunantwort ATE455300T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/141,508 US20030215460A1 (en) 2002-05-07 2002-05-07 Methods and compositions for inducing an immune response
PCT/US2002/036206 WO2003096017A1 (en) 2002-05-07 2002-10-21 Methods and compositions for inducing an immune response

Publications (1)

Publication Number Publication Date
ATE455300T1 true ATE455300T1 (de) 2010-01-15

Family

ID=29418406

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02805706T ATE455300T1 (de) 2002-05-07 2002-10-21 Verfahren und zusammensetzungen zum auslösen einer immunantwort

Country Status (12)

Country Link
US (2) US20030215460A1 (zh)
EP (1) EP1499886B1 (zh)
JP (1) JP4299777B2 (zh)
KR (1) KR100943825B1 (zh)
CN (1) CN1639569B (zh)
AT (1) ATE455300T1 (zh)
AU (1) AU2002365437B2 (zh)
CA (1) CA2484607A1 (zh)
DE (1) DE60235122D1 (zh)
DK (1) DK1499886T3 (zh)
ES (1) ES2338308T3 (zh)
WO (1) WO2003096017A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050234004A1 (en) * 2004-01-26 2005-10-20 Brett Premack Compositions and methods of use of W-peptides
US8353860B2 (en) * 2004-09-30 2013-01-15 Boston Scientific Scimed, Inc. Device for obstruction removal with specific tip structure
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8221995B2 (en) * 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
MX337287B (es) * 2009-07-10 2016-02-22 Transgene Sa Biomarcador para seleccionar pacientes y metodos relacionados.
KR101249041B1 (ko) 2010-04-28 2013-03-29 포항공과대학교 산학협력단 결합조직 성장인자를 이용한 약학적 조성물
DK3122375T3 (da) * 2014-03-28 2021-05-25 Univ Washington Through Its Center For Commercialization Vacciner mod bryst- og ovariecancer
CN107375922B (zh) * 2017-07-20 2020-06-09 南京农业大学 一种水溶性复合免疫佐剂及猪圆环病毒病疫苗
JP2019116454A (ja) * 2017-12-27 2019-07-18 国立大学法人帯広畜産大学 アジュバント
CN112263674A (zh) * 2020-11-09 2021-01-26 天津农学院 一种猪3型链球菌荚膜多糖亚单位疫苗及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5284753A (en) * 1991-03-20 1994-02-08 Neuro Probe, Inc. Multiple-site chemotactic test apparatus and method
ATE260971T1 (de) * 1992-04-01 2004-03-15 Univ Rockefeller Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US6001606A (en) * 1994-03-08 1999-12-14 Human Genome Sciences, Inc. Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby
IL113610A0 (en) * 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5874211A (en) * 1995-04-13 1999-02-23 Incyte Pharmaceuticals, Inc. Chemokine expressed in eosinophils
NZ320932A (en) * 1995-09-29 2000-01-28 Smithkline Beecham Corp Short forms of chemokine b-8
JP2001500382A (ja) 1996-09-30 2001-01-16 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド 骨髄前駆体阻害因子―１（ｍｐｉｆ―１）、単球コロニー阻害因子（ｍ―ｃｉｆ）、およびマクロファージ阻害因子―４（ｍｉｐ―４）で疾患状態を処置するための治療組成物および方法
DE19913707A1 (de) * 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunadsorber zur Sepsistherapie
JP2003516934A (ja) * 1999-10-14 2003-05-20 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒト骨髄前駆細胞阻害性因子−１（ｍｐｉｆ−１）を用いる、細胞、組織および器官の損傷を処置または予防する方法
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof

Also Published As

Publication number Publication date
AU2002365437A1 (en) 2003-11-11
US20030215460A1 (en) 2003-11-20
KR100943825B1 (ko) 2010-02-25
CN1639569A (zh) 2005-07-13
DE60235122D1 (de) 2010-03-04
EP1499886A1 (en) 2005-01-26
ES2338308T3 (es) 2010-05-06
KR20050027089A (ko) 2005-03-17
US20060034863A1 (en) 2006-02-16
DK1499886T3 (da) 2010-05-25
EP1499886B1 (en) 2010-01-13
WO2003096017A1 (en) 2003-11-20
JP2005524719A (ja) 2005-08-18
AU2002365437B2 (en) 2010-06-03
JP4299777B2 (ja) 2009-07-22
CA2484607A1 (en) 2003-11-20
CN1639569B (zh) 2012-09-05
US8637043B2 (en) 2014-01-28
EP1499886A4 (en) 2007-06-27

Similar Documents

Publication Publication Date Title
ATE455300T1 (de) Verfahren und zusammensetzungen zum auslösen einer immunantwort
SG196688A1 (en) Therapeutic human anti-il-1r1 monoclonal antibody
WO2007028047A3 (en) Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy
IL138424A0 (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
ATE471946T1 (de) Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
HUP0401591A2 (hu) Új receptor-nukleinsavak és- polipeptidek
WO2006105993A3 (en) Method for shielding functional sites or epitopes on proteins
ATE279517T1 (de) Il-17 receptor
HK1082200A1 (en) Compositions and methods for the therapy of inflammatory bowel disease
NO20001104L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende slike samt terapeutiske anvendelser derav
SG164369A1 (en) Human anti-b7rp1 neutralizing antibodies
WO2002095030A3 (en) Modulation of cd200 receptors
WO2002064057A3 (en) Use of cell penetrating peptides to generate antitumor immunity
WO2020057541A8 (en) Anti-ifnar1 antibodies for treating autoimmune diseases
EP1434854A4 (en) COMPOSITIONS USEFUL AS LIGANDS OF THE RECEPTOR TYPE RECEPTOR OF FORMY PEPTIDES AND METHODS OF USE THEREOF
TR200103012T2 (tr) Yeni kompozisyonlar
HK1025500A1 (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
DE69824023D1 (de) Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind
Nagarajan et al. Human tumor membrane vesicles modified to express glycolipid-anchored IL-12 by protein transfer induce T cell proliferation in vitro: a potential approach for local delivery of cytokines during vaccination
EP1594533A4 (en) ANTIBODY VACCINE CONJUGATES AND ITS USES
ATE409045T1 (de) Pharmazeutische zusammensetzung enthaltend löslichen fcgamma rezeptor iib
WO2005123112A3 (en) Method of enhancing the immune response to a vaccine
Barr et al. CD40 antibody as a potent immunological adjuvant: CD40 antibody provides the CD40 signal to B cells, but does not substitute for T cell help in responses to TD antigens
Li et al. 843 Development and engineering of human sialidase for degradation of immunosuppressive sialoglycans to treat cancer
TR200202702T2 (tr) Nükleer hormon reseptör fomksiyonun kaynaşmış halkalı modülatörleri.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1499886

Country of ref document: EP